INVO Bioscience Faces Delisting and Agreement Termination
Ticker: IVF · Form: 8-K · Filed: Apr 19, 2024 · CIK: 1417926
| Field | Detail |
|---|---|
| Company | Invo Bioscience, INC. (IVF) |
| Form Type | 8-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $475,000, $356,546.66, $892,825, $2,500,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, agreement-termination, financial-distress
TL;DR
INVO Bioscience is getting delisted and lost a key deal.
AI Summary
INVO Bioscience, Inc. announced on April 17, 2024, the termination of a material definitive agreement and received a notice of delisting or failure to satisfy continued listing rules. The company is incorporated in Nevada and its principal executive offices are located in Sarasota, Florida.
Why It Matters
This filing indicates significant financial distress or operational issues for INVO Bioscience, potentially leading to its removal from a stock exchange and impacting its ability to raise capital.
Risk Assessment
Risk Level: high — The company is facing delisting and termination of a material agreement, signaling severe financial or operational challenges.
Key Players & Entities
- INVO Bioscience, Inc. (company) — Registrant
- April 17, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Sarasota, Florida (location) — Address of principal executive offices
FAQ
What was the material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but does not specify the name or details of the agreement.
What are the specific reasons for the notice of delisting or failure to satisfy continued listing rules?
The filing indicates a notice of delisting or failure to satisfy continued listing rules but does not provide the specific reasons for this notice.
What is the expected timeline for the delisting process?
The filing does not provide an expected timeline for the delisting process.
Has INVO Bioscience taken any steps to address the delisting concerns?
The filing does not detail any specific steps taken by INVO Bioscience to address the delisting concerns.
What is the impact of the terminated agreement on INVO Bioscience's operations?
The filing does not specify the operational impact of the terminated material definitive agreement.
Filing Stats: 881 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-04-19 17:18:41
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INVO The Nasdaq
- $475,000 — ises. Brown Fertility paid INVO Centers $475,000 to secure the space and INVO was fully
- $356,546.66 — andlord under the assignment. INVO used $356,546.66 of the assignment proceeds to complete
- $892,825 — April 16, 2024, stockholders' equity of $892,825 in the Form 10-K for the period ended D
- $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Equity Rule"). In a decision da
Filing Documents
- form8-k.htm (8-K) — 45KB
- 0001493152-24-015388.txt ( ) — 215KB
- invo-20240417.xsd (EX-101.SCH) — 3KB
- invo-20240417_lab.xml (EX-101.LAB) — 33KB
- invo-20240417_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. INVO BIOSCIENCE, INC. By: /s/ Steven Shum Name: Steven Shum Title: Chief Executive Officer Dated: April 19, 2024 -3-